Exane Derivatives’s Zimmer Biomet ZBH Stock Holding History

Exane Derivatives’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	-$256	–	1034
2022 Q1	$256	Buy	+2	New	+$241	﹤0.01%	937
2021 Q4	–	Sell	-2	Closed	-$293	–	1084
2021 Q3	$293	Hold	2	–	–	﹤0.01%	992
2021 Q2	$314	Hold	2	–	–	﹤0.01%	988
2021 Q1	$320	Sell	2 -35	-95%	-$5.42K	﹤0.01%	839
2020 Q4	$5.55K	Sell	37 -420	-92%	-$59.3K	﹤0.01%	555
2020 Q3	$60.4K	Hold	457	–	–	0.02%	363
2020 Q2	$53K	Sell	457 -1,358	-75%	-$156K	0.01%	347
2020 Q1	$178K	Sell	1,815 -1,210	-40%	-$159K	0.05%	213
2019 Q4	$435K	Buy	+3,025	New	+$418K	0.08%	184

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Exane Derivatives's ZBH Position: Q2 2022 in Review

Exane Derivatives sold out of Zimmer Biomet (ZBH) in Q2 2022, closing a stake of 2 shares — an estimated $256 sold.

Exane Derivatives first reported a position in ZBH in Q4 2019 and held it in 9 quarters. The position peaked at $435K in Q4 2019. 957 funds tracked by Wall St. Rank hold ZBH as of Q2 2022.

Exane Derivatives reported no remaining Zimmer Biomet position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 2 Zimmer Biomet shares in Q2 2022, an estimated $256.
Exane Derivatives first reported a position in Zimmer Biomet in Q4 2019 and held it in 9 quarters.
Exane Derivatives's Zimmer Biomet position peaked at $435K in Q4 2019.
957 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.